← All trials
NCT05421429
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 7, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jun 16, 2022
- Last posted
- Jul 25, 2022
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alphamab Co., Ltd.Lead sponsor
- Central South UniversityOverall official - principal investigator
- Soochow UniversityOverall official - principal investigator
- Zhengzhou UniversityOverall official - principal investigator
- Southern Medical UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Anhui Province Cancer HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.